US, EU and UK Antitrust Enforcers Form Pharma Monitoring Taskforce

AZ’s planned Alexion acquisition may be an early target

17 Mar 2021

• By Sten Stovall

Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation.

Competition Law — Aim is to identify ways to scrutinize Pharma deals more closely • Source: Shutterstock

AstraZeneca PLC’s proposed acquisition of Alexion could become the first test balloon for the newly announced international taskforce that anti-trust regulators in the US, Europe and the UK hope can curb M&A deals that threaten competition and restrict innovation in the medical field, analysts said.

Responding to the recent stream of pharmaceutical mergers, antitrust regulators and enforcement agencies from the US, Europe and the UK...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

MBX Awaits Value-Creating Milestones, With Phase II Hypoparathyroidism Data Due Any Day

01 Sep 2025

• By Mandy Jackson

MBX Biosciences uses its Precision Endocrine Peptide (PEP) platform to create hormone therapeutics with improved efficacy, durability and tolerability in rare diseases and obesity.

The Expanding MASH Market: How Rezdiffra, Wegovy Might Coexist

01 Sep 2025

• By Joseph Haas

FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.

Quick Listen: Scrip’s Five Must-Know Things

01 Sep 2025

• By Ian Haydock

In this week's episode: Lilly’s orforglipron strong in diabetic obesity; Ascletis confident in oral GLP-1 challenger; myostatin drugs progress for obesity; an interview with OneSource’s CEO; and an analysis of Dupixent’s pipeline-in-a-product success.

Deal Watch: XOMA Buys Troubled Alkermes-Spinout Mural Oncology

29 Aug 2025

• By Joseph Haas, Xu Hu, and Lisa Takagi

Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.

Sanofi’s Wayrilz Gets Out Of The Blocks With First US Approval For ITP

01 Sep 2025

• By Alexandra Shimmings

The FDA go-ahead makes it the first for a BTK inhibitor in immune thrombocytopenia. Sanofi hopes it will mark the start of a number of indications for rilzabrutinib.